PMID: 8590264Jan 1, 1995Paper

Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
B M Gebhardt, H E Kaufman

Abstract

The time-honored approach to delivering drugs to the ocular surface is through the use of liquid drops and semisolid ointments. Such delivery systems, however, are not efficient at delivering therapeutic concentrations of drugs to the cornea and intraocularly. Over the past several years, we tested the biopolymer, collagen, as a means of delivering both hydrophilic and hydrophobic drugs to the ocular surface. This study summarizes results obtained using the hydrophobic drug, cyclosporine, incorporated into collagen shields and collagen particles. Corn oil drops containing cyclosporine were used as the control. Groups of anesthetized rabbits were fitted with collagen shields containing cyclosporine, treated topically with collagen particles containing cyclosporine suspended in an ocular surface lubricant, or given topical drops of corn oil containing cyclosporine. At intervals after a single treatment with one of the drug formulations, corneas, aqueous humor, and blood were collected for analysis of cyclosporine concentration. With either of the two collagen vehicles, peak concentrations of the drug were found in the cornea 4 hours after application. The corn oil vehicle yielded a significantly lower and earlier peak concentrati...Continue Reading

References

Feb 15, 1990·American Journal of Ophthalmology·Y F ChenH E Kaufman
Jul 1, 1988·Transplantation·J C Hill, R Maske
Sep 1, 1989·Archives of Ophthalmology·D G HwangL A MacGowan-Smith
Sep 1, 1981·Archives of Ophthalmology·J D Salisbury, B M Gebhardt

❮ Previous
Next ❯

Citations

Jun 9, 2001·International Journal of Pharmaceutics·C H LeeY Lee
Oct 31, 1998·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·E Grześkowiak
Nov 7, 2003·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·F LallemandR Gurny
May 24, 2012·TheScientificWorldJournal·Burçin YavuzNurşen Unlü
Dec 18, 2013·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·K BellF H Grus
Jun 19, 2012·Expert Opinion on Drug Delivery·Priyanka PahujaPravin Pawar
Jul 9, 2002·Drug Development and Industrial Pharmacy·Indu Pal Kaur, Meenakshi Kanwar
Feb 23, 2011·The Ocular Surface·Gary D Novack
Feb 20, 2009·Clinical Pharmacology and Therapeutics·G D Novack
Mar 15, 2005·Clinical Pharmacokinetics·Diane D-S Tang-Liu, Andrew Acheampong
May 28, 2020·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Gary D Novack, Melissa Barnett
Jun 14, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Zahraa H F Al-SaediSai H S Boddu
Jan 1, 1996·Drug Delivery·T L Whateley
Aug 15, 1998·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·W Friess

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.